INTRODUCTION
Iron deficiency (ID) and iron deficiency anemia (IDA) are common clinical conditions in medical practice, yet there are still some uncertainties when it comes to their correct diagnosis. 1 Iron deficiency anemia is easily recognizable when associated with decreased intake or increased requirements for iron, like chronic blood loss and malabsorption. The most accessible laboratory parameters that are objectively measured and used as biomarkers for ID are serum iron (Fe), transferrin saturation (TSAT) and serum ferritin (Ferr), which decrease in IDA. 2 Diagnosis of ID and IDA is more complicated when they combine with acute or chronic inflammation, because transferrin, which is used for TSAT calculation, and ferritin are altered in acute-phase reactions, typical for anemia in chronic diseases (ACD), and despite normal or increased iron stores, patients with inflammation have decreased serum iron, low TSAT and normal or elevated serum ferritin. 3, 4 Bone marrow staining for iron to determine iron stores is not considered as a standard of care for the diagnosis of IDA or ACD. Soluble transferrin receptor (sTfR) is a biomarker of erythropoietic activity and tissue ID. It reflects the erythropoiesis demands for iron, and is elevated in ID. Unlike the former three laboratory parameters, it is not affected by inflammation and infections. 5, 6 Erythropoiesis is a dynamic process that depends on the balance between iron requirements and DOI: 10.2478/folmed-2018-0065
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supply to erythroblasts for hemoglobin synthesis. When iron delivery to erythroblasts is compromised, erythropoiesis is limited by ID. 7 Iron restriction of erythropoiesis is caused by reduced or depleted body iron stores as absolute ID and IDA. Another cause is the impaired mobilization with inadequate delivery of iron despite its presence in the macrocytemacrophage system and the liver-iron sequestration and functional ID (FID), typical characteristics of inflammation, infections, malignant processes and components of ACD. 7, 8 As a result of this imbalance, the normal hemoglobinization in erythroblasts is impaired with production of reticulocytes and erythrocytes with reduced hemoglobin content. Reticulocyte hemoglobin content (CHr) assesses directly the incorporation of iron into erythrocyte hemoglobin and thus estimates the current functional iron available for erythrocyte production. 9, 10 Due to the short life span of reticulocytes in circulation, CHr is a sensitive biomarker for assessing iron-deficient erythropoiesis and FID. 9, 10 The aim of this study was to compare the clinical significance of biomarkers of ID in diagnosing IDA and iron-deficient erythropoiesis in patients with anemia.
MATERIALS AND METHODS

Patients
A total of 103 consecutive, newly diagnosed, untreated patients with anemia over 18 years of age were included in the study. They were consulted or diagnosed and treated in Hematology Clinic of Military Medical Academy, Sofia. Prior written informed consent of patients was obtained for blood sampling as a part of the common diagnostic work-up process. According to WHO guidelines anemia was diagnosed at a hemoglobin concentration less than 130 g/l for men and less than 120 g/l for women. 11 Subject exclusion criteria were hemolytic and hereditary anemia, vitamin B12 or folate deficiency, active bleeding, blood transfusions within the last three months, renal failure patients currently on dialysis as well as patients receiving iron supplementation. The median age of the patients was 58.2 years (22 to 91), of which 41 were men (39.81%) and 62 were women (60.19%). The diagnostic work-up process identified patients with gastrointestinal diseases (30), gynecological diseases (26), hematological diseases (18) and solid tumors (5), without bone marrow involvement, renal diseases (13) , rheumatic diseases (6) and pulmonary diseases (5) .
Laboratory methods
Routine laboratory testing included complete blood count and iron profile. All laboratory investigations were carried out in the Central Clinical Laboratory of Military Medical Academy, Sofia. The laboratory participates in external quality assessment and has relevant certificates. Blood samples were taken in a fasting state in the morning and the laboratory analysis was carried out within two hours. Hematological parameters -hemoglobin (Hb), reticulocytes (Ret), CHr were measured as complete blood count on the ADVIA 2120 automatic hematologic analyzer. A CHr value less than 28 pg was diagnostic for iron-deficient erythropoiesis. 9, 12 Biochemical markers of iron metabolism -serum iron, TSAT and ferritin, were measured on the Beckman-Coulter Olympus 680 automated biochemical analyzer, as well as C-reactive protein (CRP) as a parameter for inflammation. A TSAT value less than 16% and a ferritin value less than 30 μg/l were used to diagnose IDA. [13] [14] [15] [16] The concentration of sTfR was determined via Beckman-Coulter analyzer Access 2 with Access® sTfR immunoassay system. The reference ranges for sTfR were: 0.9 -2.1 mg/l. The sTfR-ferritin index (sTfR-F index) was calculated using the follow equation: sTfR-F index = sTfR(mg/l)/logFerr(μg/l) where log is a decimal logarithm. 5, 12 Table 1 presents the main laboratory parameters of the study population of anemic patients.
A Thomas-plot analysis, which explores CHr to evaluate hemoglobinization against sTfR/logFerr ratio for total body iron assessment, was performed (Fig. 1) . It was utilized to define the erythropoiesis in normal iron status, latent ID, absolute ID with depleted stores, and FID combined with ACD -a total of 4 quadrants. 12 The cut-off value for the sTfR/logFerr ratio was 1.5 for patients with CRP<5 mg/l and 0.8 -for CRP>5 mg/l. A CHr value less than 28 pg defined impaired red cell hemoglobinization with FID, irrespective of the iron stores -quadrant 3 and 4.
statisticaL anaLysis Descriptive data analysis was used for categorical and continuous variables and for comparison of different biomarkers of ID in anemia. Shapiro-Wilk test was applied to investigate the normality of the data. Mann-Whitney U test was used to compare two groups. Correlation analysis was completed with non-parametric test of Spearman. Logistic regression analysis was performed to assess the predictive probability of iron-deficient erythropoiesis (CHr<28 pg) in anemia depending on laboratory parameters of iron metabolism. In addition, a receiver operating characteristic (ROC) curve was utilized with calculation of the area under curve (AUC) to illustrate the diagnostic performance of sTfR-F index as regard sensitivity-specificity ratio and determine an optimal cut-off value. Significance of conclusions was determined at p<0.05. The statistical analysis was performed with SPSS-19 statistical software.
RESULTS
When TSAT<16% was used, 79 patients were diagnosed with IDA (76.7%), while Ferr<30 μg/l diagnosed only 50 patients with IDA (48.5%). Thomas-plot analysis found 76 patients with anemia and ID (73.8%). Fifty-six patients (54.4%) of them had iron-restricted erythropoiesis with absolute or functional ID (quadrant 3 and 4) consistent with IDA, and 20 patients (19.4%) had latent ID (quadrant 2) with decreased iron stores, but still normal hemoglobinisation (Table 2) . The medians of the investigated laboratory parameters of iron metabolism of the anemic patients with CHr<28 pg were significantly different from those of the patients with higher CHr (Table 3) . We found lower levels of serum iron, TSAT and ferritin and higher levels of sTfR and sTfR-F index in anemic patients with CHr<28 pg (p<0.001).
Reticulocyte hemoglobin content of all 103 patients with anemia showed a high positive correlation with serum iron (ρ=0.648, p<0.001), TSAT (ρ=0.757; p<0.001), ferritin (ρ=0.647; p<0,001) and a high negative correlation with sTfR (ρ=-0.620; p<0.001) and sTfR-F index (ρ=-0.715; p<0.001).
A logistic regression model was used to determine the predictive value of biomarkers of ID for the presence of iron-deficient erythropoiesis in anemia (CHr<28 pg). According to the logistic (Fig. 2) , with area under curve of 0.866 (95%CI: 0.791-0.941; p<0.001). The optimum cut-off point for the sTfR-F index of this analysis was 1.35 with sensitivity of 82.1% and a specificity of 80.9%.
DISCUSSION
The early diagnosis of IDA is important for clinicians, because IDA requires iron replacement therapy even in inflammation, whereas ACD is corrected by treatment of the underlying disease. 1, 3 Iron treatment is not harmless and may cause gastrointestinal complications and worsen infectious diseases. 17 Serum iron is an inexpensive test, but its single determination and interpretation may lead to diagnostic mistakes due to rapid iron metabolism and influence of food intake, inflammation, and circadian variations. 18 Laboratory parameters TSAT and ferritin (Table 4 ). Significant effect showed only sTfR-F index (p=0.011). The model was statistically significant regarding the predictive value for iron-deficient erythropoiesis in anemia (χ(5)=77.248; p<0.001). For this model AUC was 0.939, which corresponded to an excellent quality, with a percentage of correctly recognized in the group patients of 88.3%. The ROC curve of the sTfR-F index was plotted to assess its discrimination power to evaluate iron-deficient erythropoiesis (CHr<28 pg) in anemia have limited diagnostic value for absolute ID in iron sequestration syndrome such as inflammation and ACD. Nevertheless, they are routinely used in clinical practice for their easy accessibility. Their results are comparable, while still problems with standardization of the sTfR exist, and institutions are recommended to develop their own reference ranges for clinical diagnosis. 1, 17, 19 The comparison of the results when different biomarkers of ID were used in our patients with anemia shows that their diagnostic significance depends on the selected biomarker and their cut-off value. Seventy-nine out of the 103 patients were diagnosed with IDA by TSAT<16% (76.7%), while Thomas-plot analysis detected 76 patients with anemia and ID (73.8%), and 56 (54.4%) of them had iron-restricted erythropoiesis and IDA. Nine patients diagnosed with IDA and TSAT<16% (8.7%) had normal iron status by Thomas-plot analysis, while 1 patient had TSAT>16% and FID. Transferrin saturation reflects the iron available in the blood. 17 It provides only indirect information about the delivery of iron to the bone marrow and does not reflect the status of the iron stores. 20 Circadian changes in iron concentration cause fluctuations of TSAT and transferrin synthesis and clearance may vary in conditions like protein deficiency, chronic diseases and infections, liver diseases, nephritic syndrome. 18 Both decrease in serum iron and concentration of transferrin, which is a negative acute-phase protein, may cause TSAT changes in inflammation states. 4, 8 These factors reduce the specificity of TSAT for IDA and represent a possible explanation of the differences found here in diagnosing IDA with different biomarkers of ID.
Ferritin values below 30 μg/l revealed 50 out of 103 patients with IDA (48.5%) and Thomasplot analysis discovered 56 patients (54.4%) with iron-restricted erythropoiesis and IDA. Twenty-eight patients with Ferr>30 μg/l (27.2%) were diagnosed with ID by Thomas-plot analysis, and 14 (13.6%) of them had IDA; normal iron status was determined in 2 patients (1.94%) with Ferr<30 μg/l. Serum ferritin provides indirect information about the body iron stores, mainly about liver reserves. 17 Its low value is always indicative of ID. 1, 20 Serum ferritin is a positive acute-phase protein and it increases in acute and chronic conditions and inflammatory diseases irrespective of the iron status. 4 It is altered in malignant diseases, hepatic diseases, and poses diagnostic difficulties in IDA. Soluble transferrin receptor reflects the erythropoiesis demands for iron, and may still be normal if hemoglobinization is normal despite depleted iron stores. 6, 15 These factors are likely to explain to some extent the detected differences in the diagnosis of IDA and iron-deficient erythropoiesis in our anemic patients by serum ferritin and Thomas-plot analysis.
Similar results were observed in a study by Enko et al. comparing laboratory biomarkers and definitions of ID for assessment of iron status in patients regardless of anemia; prevalence of ID varied with marker selection and definition. 21 Reticulocyte hemoglobin content is often low in iron-replete patients with thalassemia and hemoglobinopathies and can be elevated in iron-deficient patients with confounding megaloblastic anemia, sTfR level is elevated in hemolytic anemias and secondary to use of erythropoiesis stimulating agents, causing diagnostic limitations. 6, 9 In our study the influence of therapy and known factors that may reduce specificity of these laboratory parameters was controlled by applying exclusion criteria.
As expected, we found positive correlation between CHr as a marker of hemoglobinization and serum iron, TSAT and ferritin, and negative correlation between CHr and sTfR and sTfR-F index in tested patients with anemia. This study also shows a significant and consistent increase in sTfR and sTfR-F index and a reduction in ferritin, TSAT and iron in anemic patients with iron-deficient erythropoiesis (CHr<28 pg), with medians below and over the reference limits respectively. It is also noteworthy that in patients with CHr>28 pg, the medians of ferritin, sTfR and sTfR-F index are within the reference limits. Besides, the medians of serum iron and TSAT, which as mentioned before, are subject of more influenced variations, are just below the lower limits, but still significantly different from the patients with iron-deficient erythropoiesis. Despite their reduction, erythropoiesis in the group with CHr>28 pg is normal, with probably enough available iron supply for hemoglobinisation.
According to the logistic regression analysis results for the predictive value of the investigated parameters of iron metabolism, in regard to the presence of iron-deficient erythropoiesis in anemia (CHr <28 pg), the mutual controlled influence of the five prediction variables in the model prove sTfR-F index only as independent statistically significant (p=0.011). The level of sTfR reflects the erythropoiesis demands for iron and it is not affected by acute-phase reactions. 5, 6, 17 Iron-deficient erythropoiesis is the most common cause for its elevation and sTfR is proposed for the diagnosis of IDA in patients with complicated anemia in inflammation. 6, 22 Determination of sTfR and ferritin, when applied in combination as sTfR/logFerr, reflects the balance between the iron, inflammation and erythropoietic iron requirements of the body. 17 Evaluation of sTfR-F index and CHr together could be further utilized to diagnose iron-deficient erythropoiesis in anemia. The sTfR-F index distinguishes IDA, especially in terms of chronic disease, better than sTfR and ferritin alone, and its combination with CHr assesses iron metabolism and FID. 5, 12 The optimal cut-off value for sTfR-F index as a classifier of iron-deficient erythropoiesis in anemia (CHr<28 pg) according to the highest sensitivity and specificity is 1.35. This value is in concordance with previous studies for IDA utilizing the same laboratory chemiluminescence immunoassay method to determine sTfR. 19, 23 The area under ROC curve -AUC of 0.866, identifies sTfR-F index as a very good diagnostic criterion for IDA.
In our study, anemic patients were divided into groups by CHr value as a threshold of iron-deficient erythropoiesis -a condition that is important for clinicians because it necessitates iron supplementation. However, if patients were grouped another way, results may differ. Another limitation is that the study is based on a single measurement point to assess ID. A prospective study with followup measurements during iron supplementation is needed to validate the diagnostic performance of the cut-off value for treatment.
CONCLUSIONS
The diagnosis of IDA in patients with anemia depends on the applied laboratory parameters as biomarkers of ID and analysis of TSAT or ferritin alone may lead to diagnostic failures and therapeutic difficulties. Combining sTfR-F index and CHr to assess iron-deficient erythropoiesis in patients with anemia in addition to ferritin and TSAT could contribute to improving the diagnosis of IDA in clinical practice.
